Want to see KRMD full AI Analyst Report?
KRMD Stock Chart & Stats
$3.20
$0.25(6.53%)
At close: 4:00 PM EDT
$3.20
$0.25(6.53%)
Day’s Range― - ―
52-Week Range$2.86 - $6.61
Previous Close$4.08
Volume158.41K
Average Volume (3M)255.62K
Market Cap
$143.59M
Enterprise Value$202.96M
Total Cash (Recent Filing)$8.29M
Total Debt (Recent Filing)$3.24M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 10, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding46,171,900
10 Day Avg. Volume198,412
30 Day Avg. Volume255,617
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)15.74
Price to Sales (P/S)6.52
P/FCF Ratio-570.81
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue4.50
Enterprise Value/Gross Profit7.26
Enterprise Value/Ebitda-199.39
Forecast
1Y Price Target
$6.60Price Target Upside106.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$48.04M
Bulls Say, Bears Say
Bulls Say
Recurring Patient BaseA large chronic patient base creates repeat demand for pumps, administration sets and other consumables as therapies continue over time. This recurring utilization can improve revenue visibility, support customer retention and provide a durable foundation for future product adoption.
Growth And Margin ExpansionStrong quarterly growth alongside higher gross margin indicates improving commercial traction and operating quality, rather than growth purchased through declining economics. Sustained margin performance would expand reinvestment capacity and improve the potential for durable earnings conversion.
Liquidity And Low LeverageConservative leverage and recently positive cash generation give the company financial flexibility to fund operations and selected growth initiatives without relying heavily on external capital. This resilience is valuable while profitability continues transitioning toward a more sustainable level.
Bears Say
Profitability Not Yet SustainedThe company has not yet demonstrated sustained profitability, so revenue growth is still translating into losses at the full-year level. Continued negative returns can constrain internally funded investment, weaken financial compounding and leave execution dependent on further margin improvement.
International Growth TimingDelayed international launches and conversions make the growth outlook more dependent on execution timing than on demand alone. Revenue deferrals can create uneven results over the next several quarters and postpone the scale benefits expected from distributor-led expansion.
Delayed Oncology ExpansionThe withdrawn submission removes or postpones a previously modeled U.S. oncology opportunity and requires the company to redirect development toward other molecules. That delay reduces near-term diversification and makes future growth more dependent on the existing infusion franchise.
REPRO-MED Systems News
KRMD FAQ
What was REPRO-MED Systems’s price range in the past 12 months?
REPRO-MED Systems lowest stock price was $2.86 and its highest was $6.61 in the past 12 months.
What is REPRO-MED Systems’s market cap?
REPRO-MED Systems’s market cap is $143.59M.
When is REPRO-MED Systems’s upcoming earnings report date?
REPRO-MED Systems’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were REPRO-MED Systems’s earnings last quarter?
REPRO-MED Systems released its earnings results on Aug 05, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.018 by $0.028.
Is REPRO-MED Systems overvalued?
According to Wall Street analysts REPRO-MED Systems’s price is currently Undervalued.
Does REPRO-MED Systems pay dividends?
REPRO-MED Systems does not currently pay dividends.
What is REPRO-MED Systems’s EPS estimate?
REPRO-MED Systems’s EPS estimate is -0.02.
How many shares outstanding does REPRO-MED Systems have?
REPRO-MED Systems has 46,171,900 shares outstanding.
What happened to REPRO-MED Systems’s price movement after its last earnings report?
REPRO-MED Systems reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.018. Following the earnings report the stock price went down -13.801%.
Which hedge fund is a major shareholder of REPRO-MED Systems?
Currently, no hedge funds are holding shares in KRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
REPRO-MED Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.60 (106.25% Upside)
$6.60 (106.25% Upside)
Blogger Sentiment
Neutral
KRMD Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $101.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.77%
12-Months-Change
Fundamentals
Return on Equity
-10.63%
Trailing 12-Months
Asset Growth
9.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
REPRO-MED Systems
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems. These comprehensive systems encompass components such as the FREEDOM60 and FreedomEdge syringe drivers, alongside specialized HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. Beyond their product range, KORU Medical also supplies educational content and training materials to healthcare professionals, patients, and patient advocates. The distribution of their products is managed through a combination of direct sales efforts, partnerships with medical device distributors, and online channels. Established in 1980, the firm's corporate headquarters are situated in Chester, New York.
KRMD Company Deck
KRMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful operational and financial achievements — record quarterly revenue ($12M, +18% YoY), strong domestic (+12% YoY) and international (+59% YoY) performance, margin expansion (65.1% in Q2) and return to positive net income and adjusted EBITDA — alongside strategic progress (tech acquisition, Freedom360 development, active 510(k) for deferoxamine). Offsetting items include near-term timing and execution risks: a moderated international ramp pushing some revenue into 2027, the U.S. Phesgo withdrawal delaying oncology entry, variability in pharma services (–35% YoY), and multi-year timelines for connected technology and regulatory approvals. Overall, highlights substantially outweigh the lowlights, though some growth is timing-dependent.View all KRMD earnings summariesKRMD Stock 12 Month Forecast
Average Price Target
$6.60
▲(106.25% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Utah Medical Products
―
Microbot Medical
―
―
Ownership Overview
17.49% Insiders
7.79% Mutual Funds
0.40% Other Institutional Investors
65.98% Public Companies and
Individual Investors